CF has appointed Haseeb Ahmad as a Board Advisor to CF, bringing 25 years of life sciences leadership experience and a distinguished record of creating multi-billion dollar brands from primary care to rare disease, across mature and growth markets.
Throughout his career, Haseeb has built and led high-performing teams including at leading pharmaceutical companies. He is also a vocal advocate and industry ambassador for expanding access to innovative medicines.
With over two decades of life sciences experience, Haseeb was most recently President for Novartis Europe having previously been President for Novartis Gene Therapies in the US. Prior to this, he was the Global Head of Value & Access and Commercial Development at Novartis and then Managing Director of Novartis UK, Ireland & Nordics. While at Novartis, Haseeb also acted as Government Advisor for Innovation Expert Group and acted as President and Chairman for ABPI prior to that. Before joining Novartis, he held a long career with MSD including country Managing Director roles in Ireland and Greece.
There is a new era of the potential for partnership between health systems and life sciences that leverages advances in data, digital insights and AI to support the adoption of innovation and improvement of patient outcomes. The promise of advances in fields with exciting breakthroughs including in cardiovascular, obesity, oncology, dementia now combined with advances in data, digital insights and AI show exciting opportunities to accelerate discovery, support earlier intervention, and enable more productive and cost-effective delivery.
Achieving this requires far more than simply gaining regulatory approval, market access and reimbursement. Those achievements are just the beginning of ensuring patients can gain access to innovative diagnostics and therapies. There are huge barriers to systems being ready to adopt these new innovations, and to life sciences companies being equipped to meet these challenges.
CF will support clients across the entire health sector to meet these challenges, utilising Haseeb’s unique insights and experience to continue making an enduring positive impact in health and healthcare across its whole portfolio of activity including in health systems, life sciences, health investing, data, digital insights and AI.
Haseeb Ahmad, new CF Board Advisor comments:
“CF’s deep–rooted experience within the NHS and wider health systems, combined with unique data insights and expertise within life sciences make for an exciting combination towards tackling the wider challenges the health sector faces. I have admired the work and insights from CF for some time, I’m delighted to be able to bring my knowledge to such a passionate and forward-thinking team – and to support the firm’s mission of making a lasting impact in health and healthcare.”
Hannah Farrar, CF CEO says:
“I’m delighted to welcome Haseeb to the CF Board. He brings a wealth of knowledge and strong credentials from over 20 years in the life sciences sector which will be hugely valuable as we continue to expand and strengthen CF’s capabilities across the industry. His appointment marks another exciting step in the next phase of CF growth and we’re thrilled to have him on board.”
Ben Richardson, CF Managing Partner comments:
“I’m delighted to have the chance to work closely with Haseeb again, and I look forward to exploring together how we can help foster partnerships across life sciences and health systems and leverage these advancements to make a positive impact in health and healthcare across Europe and around the world.”
Find out more about our services in life sciences and get in touch today.
